Bank of New York Mellon Corp boosted its position in Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) by 0.1% during the first quarter, Holdings Channel reports. The institutional investor owned 112,786 shares of the biotechnology company’s stock after buying an additional 149 shares during the period. Bank of New York Mellon Corp’s holdings in Aevi Genomic Medicine were worth $210,000 at the end of the most recent quarter.

Separately, Teachers Advisors LLC purchased a new position in shares of Aevi Genomic Medicine during the fourth quarter worth $204,000. Hedge funds and other institutional investors own 27.97% of the company’s stock.

Shares of Aevi Genomic Medicine, Inc. (GNMX) opened at 1.15 on Thursday. Aevi Genomic Medicine, Inc. has a 52-week low of $0.98 and a 52-week high of $6.89. The company has a 50-day moving average of $1.28 and a 200 day moving average of $2.43. The company’s market capitalization is $42.68 million.

Aevi Genomic Medicine (NASDAQ:GNMX) last released its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by $0.02. Analysts predict that Aevi Genomic Medicine, Inc. will post ($1.08) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/10/aevi-genomic-medicine-inc-nasdaqgnmx-stake-boosted-by-bank-of-new-york-mellon-corp.html.

Several research firms recently commented on GNMX. Jefferies Group LLC reaffirmed a “hold” rating and issued a $1.50 price objective on shares of Aevi Genomic Medicine in a research report on Monday. UBS AG reaffirmed a “positive” rating on shares of Aevi Genomic Medicine in a research report on Wednesday, May 10th. Finally, ValuEngine cut shares of Aevi Genomic Medicine from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease.

Want to see what other hedge funds are holding GNMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aevi Genomic Medicine, Inc. (NASDAQ:GNMX).

Institutional Ownership by Quarter for Aevi Genomic Medicine (NASDAQ:GNMX)

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.